As the year charges on, many are beginning to close out their fiscal years and start projecting/planning/reserving for next year. In light of that, I thought it would be interesting to take a moment to discuss a particular “hot topic” during the 2015 asbestos and risk-related conference circuit: the malignant synergy between asbestos, smoking and lung cancer.
The epidemiological link between smoking and lung cancer has been widely known and accepted. For some time, in cases alleging lung cancer due to asbestos exposure, values have been kept somewhat lower when a plaintiff has extensive smoking history.
Now, more recent studies have revealed a new finding — one that may have great impact on the value of such cases. These studies are finding that for a person who smokes and has also been exposed to asbestos, there is a higher risk of developing lung cancer than someone who only smoked (with no asbestos exposure) or who was exposed to asbestos with no smoking history. In other words, a smoker who was exposed to asbestos would have a much greater risk of developing lung cancer than he/she would without the asbestos exposure.
So what does this mean? Many defendants have already seen a recent upward trend in lung cancer filings. An AM Best Special Report issued in October 2013 stated:
“In addition to more traditional mesothelioma filings, the volume of lung cancer cases appears to be rising as more attorneys seek higher settlements in the face of more successful suits relative to past settlements.”
The report goes on:
“Over the years, some studies have noted an increased likelihood of developing cancer if exposed to both asbestos and tobacco and an even higher probability if asbestosis (scarring of the lung tissue caused by asbestos fibers) is present.”
The growing acceptance of a malignant synergy between asbestos exposure, smoking and lung cancer may have a lasting effect not only on how many lung cancer claims are filed, but also on how they are valued going forward. These claims may have been discounted before (especially where smoking history was extensive and well-documented), but now they may be valued higher due to the findings of these recent studies.
In our work with major asbestos defendants, including using The Ligado Platform to transform their claims administration, KCIC will be watching to see if filings continue upwards, as well as how they are valued.
Never miss a post. Get Risky Business tips and insights delivered right to your inbox.
Mesothelioma can be caused by genetic factors, specifically the presence of the BAP1 gene. If a claimant has perito… https://t.co/jYePZegmku
The drug and medical device industry has seen an explosion of innovation, but new issues and liabilities are surfac… https://t.co/ItWPJ5sKK5
The Ligado Platform is the answer for companies that have high-stakes, high-value, high-volume claims or cases in t… https://t.co/9Oy4e0ZOiJ
You can access our Bankruptcy Evidence Verification (BEV) tool in two ways. See how and why it's beneficial in the… https://t.co/CktuXOeFa8
The Ligado Platform is the answer for companies that have high-stakes, high-value, high-volume claims or cases in t… https://t.co/TCy0BFBSbo
KCIC's core values are the heart of our company's identity. One of the values is Achievement with Flexibility. Lear… https://t.co/5CZ5XiemfV
Solvency II is affecting run-off insurers' finances. See how and why it will continue to put pressure on insurance… https://t.co/7Olav8Bsov
In one week, we're packing our boots and heading to Austin, TX for the DRI Asbestos Medicine Conference. Each year… https://t.co/F4aaFCtfX9
The drug and medical device industry has seen an explosion of innovation, but new issues and liabilities are surfac… https://t.co/59bBkxwjuo
Megan Shockley combines her broad technical skills with an ability to lead client teams on a variety of projects. For example, she helps clients deploy KCIC’s Ligado Platform for claims management — helping manage their mass-tort data, especially in the asbestos personal injury arena.Learn More About Megan